RTW Biotech Opportunities Ltd Closed Period Notification
27 Febrero 2024 - 1:00AM
RNS Regulatory News
RNS Number : 5032E
RTW Biotech Opportunities Ltd
27 February 2024
LEI:
549300Q7EXQQH6KF7Z84
27 February 2024
RTW Biotech Opportunities
Ltd
(the "Company")
Closed Period
Notification
Compliance with the Market
Abuse Regulation (MAR)
The Company announces that it is
satisfied that all inside information which the directors and the
Company may have in the period leading up to the announcement of
the Annual Financial Report for the year ended 31 December 2023 has
been notified to a Regulated Information Service (RIS). The Company
is therefore not prohibited from purchasing its own securities or
issuing shares during the closed period (as defined by MAR) which
ends on the date of the announcement of the Annual Financial
Report.
If, in the period leading up to the
announcement of the Annual Financial Report, the directors of the
Company come into possession of any inside information, this will
be notified to a RIS before any such transactions are
undertaken.
The closed period will last until
the Annual Financial Report in respect of the year ended 31
December 2023 is published, which is expected to be on or around 28
March 2024.
For
Further Information:
RTW
Investments, LP
|
+44
(0)20 7959 6361
|
Woody Stileman, Managing
Director
Krisha McCune, Director, Investor
Relations
|
|
|
|
About
RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCQKABPABKDNBB
Rtw Biotech Opportunities (LSE:RTW)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Rtw Biotech Opportunities (LSE:RTW)
Gráfica de Acción Histórica
De May 2023 a May 2024